| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2937584 | JACC: Basic to Translational Science | 2016 | 7 Pages |
SummaryTranslational investigators and companies face a challenging economic environment when seeking funds to move pre-clinical stage research into human testing and beyond. Specifically, funding for cardiovascular research and product development is difficult to secure, whether from the NIH, venture capitalists, or industry. But new funding models for advancing patient-oriented science to the commercial sector are emerging. Boston-based Broadview Ventures, created by the Leducq Family Trust, promotes the development of technology for the diagnosis and treatment of cardiovascular disease and stroke through direct equity-based investments. It targets early stage companies seeking to fund proof-of-concept for technologies that hold promise as future breakthroughs for patient care. With 27 such investments over the last seven years, Broadview has considerable experience in the seed/early-stage space, and its investment model is demonstrating early signs of success. Broadview actively seeks collaborations with world-class translational investigators, inventors, and their companies, and welcomes scientific inquiries, discussion and proposals for funding.
